<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00074269</url>
  </required_header>
  <id_info>
    <org_study_id>UCSD-020815</org_study_id>
    <secondary_id>CDR0000343758</secondary_id>
    <nct_id>NCT00074269</nct_id>
  </id_info>
  <brief_title>Allogeneic Stem Cell Transplant After ATG, High-Dose Melphalan, and Fludarabine for Patients With Metastatic Breast Cancer</brief_title>
  <official_title>Pilot Study Of Allogeneic Peripheral Blood Progenitor Cell Transplantation In Patients With Chemotherapy-Refractory Or Poor-Prognosis Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Diego</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute (NCI)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Diego</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy, such as fludarabine and melphalan, before a donor peripheral
      blood stem cell transplant helps stop the growth of tumor cells. It also stops the patient's
      immune system from rejecting the donor's stem cells. The donated stem cells may replace the
      patient's immune system and help destroy any remaining tumor cells (graft-versus-tumor
      effect). Giving an infusion of the donor's T cells (donor lymphocyte infusion) after the
      transplant may help increase this effect. Sometimes the transplanted cells from a donor can
      also make an immune response against the body's normal cells. Giving antithymocyte globulin,
      cyclosporine, and methotrexate before or after the transplant may stop this from happening.

      PURPOSE: This phase II trial is studying how well antithymocyte globulin, high-dose
      melphalan, fludarabine, and allogeneic peripheral stem cell transplant work in treating
      patients with metastatic adenocarcinoma of the breast.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:

      Primary

        -  Determine the toxicity and tolerability of allogeneic peripheral blood stem cell
           transplantation after a nonmyeloablative preparative regimen comprising anti-thymocyte
           globulin, high-dose melphalan, and fludarabine in women with chemotherapy-refractory or
           poor-prognosis metastatic adenocarcinoma of the breast.

        -  Determine the ability of this preparative regimen to facilitate long-term engraftment of
           allogeneic stem cells and lymphocytes in these patients.

        -  Determine the response in measurable/evaluable disease and its temporal relationship to
           the preparative chemotherapy used and to the onset of clinical graft-versus-host disease
           (GVHD) in patients treated with this regimen.

      Secondary

        -  Determine the progression-free and overall survival of patients treated with this
           regimen.

        -  Determine the tumor response and its temporal relationship to administration of
           high-dose chemotherapy and to the onset of GVHD in patients treated with this regimen.

        -  Determine the frequency and durability of the induction of full donor chimerism of
           lymphocytes in patients treated with this regimen.

      OUTLINE: This is a nonrandomized, pilot study.

        -  Nonmyeloablative preparative regimen: Patients receive fludarabine IV over 30 minutes on
           days -8 to -4, anti-thymocyte globulin IV over 4 hours on days -7 to -4, and high-dose
           melphalan IV over 30 minutes on days -3 and -2.

        -  Graft-versus-host disease (GVHD) prophylaxis: Patients receive cyclosporine IV (and then
           orally when tolerated) every 12 hours beginning on day -4 and tapered after day 42 (if
           no GVHD occurs) or after day 90 (if grade I acute GVHD occurs). Patients also receive
           methotrexate IV on days 1, 3, and 6.

        -  Allogeneic peripheral blood stem cell transplantation (PBSCT): Patients undergo
           allogeneic PBSCT on day 0. Patients also receive filgrastim (G-CSF) IV or subcutaneously
           beginning on day 0 and continuing until blood counts recover.

        -  Donor lymphocyte infusion (DLI): Patients who show disease progression or fail to
           achieve full donor type T-cell chimerism (at least 90% donor derived T-cells) by the
           90-day assessment posttransplantation, and have no evidence of active GVHD may receive
           DLI. Patients who have unresponsive disease with no active GVHD receive subsequent DLIs
           every 6-8 weeks.

      Patients are followed at 1, 3, 6, 12, 18, 24, 30, and 36 months.

      PROJECTED ACCRUAL: A total of 10 patients will be accrued for this study.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Terminated early due to poor enrollment
  </why_stopped>
  <start_date>July 2003</start_date>
  <completion_date type="Actual">March 2008</completion_date>
  <primary_completion_date type="Actual">March 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Adverse Events Rate</measure>
    <time_frame>5 years post transplant</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Facilitation of Long-term Engraftment</measure>
    <time_frame>post treatment</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and Severity of Acute and Chronic Graft-versus-host Disease (GVHD)</measure>
    <time_frame>post treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression-free Survival</measure>
    <time_frame>post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response (Partial and Complete) as Measured at 1, 3, 6, and 12 Months Post Allografting and Within 1 Week After the Onset of Documented GVHD if &gt; 1 Month Separates Any of the Response Evaluation Timepoints</measure>
    <time_frame>post treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency and Durability of the Induction of Full Donor Chimerism of Lymphocytes as Measured at 1, 3, 6, and 12 Months Post Allografting</measure>
    <time_frame>post treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>anti-thymocyte globulin</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>filgrastim</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>graft-versus-tumor induction therapy</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>therapeutic allogeneic lymphocytes</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>fludarabine phosphate</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>melphalan</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>methotrexate</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>peripheral blood stem cell transplantation</intervention_name>
    <arm_group_label>treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:

          -  Histologically confirmed adenocarcinoma of the breast

               -  Metastatic disease

          -  Meets 1 of the following criteria:

               -  Chemotherapy-unresponsive disease defined as 1 of the following:

                    -  Less than a partial response to 2 consecutive chemotherapy regimens that
                       included an anthracycline and a taxane in combination or succession

                    -  Progression of disease during or within 3 months of completion of a taxane,
                       anthracycline, or platinol-based regimen

               -  Histologically confirmed tumor involvement on bone marrow biopsy

          -  Measurable or evaluable disease* defined as the following:

               -  Bidimensionally reproducible measurable mass by physical examination,
                  ultrasonography, radiography, CT scan, or MRI

               -  Evaluable lesions apparent on clinical exam, x-ray, CT scan, or MRI which do not
                  fit the criteria for measurability (e.g., ill-defined post-surgical masses or
                  masses assessable in 1 dimension only)

                    -  Elevation of biological markers (e.g., CA 27.29) is considered evaluable
                       disease NOTE: *Bone lesions or pleural or peritoneal effusion alone are not
                       considered measurable or evaluable disease

          -  Appropriate candidate for allogeneic stem cell transplantation

          -  No active CNS metastases

          -  Available HLA-identical sibling donor

               -  6/6 antigen match

               -  Donor CD34 cells at least 2 times 10^6/kg recipient weight

          -  Hormone receptor status:

               -  Estrogen receptor negative or positive

                    -  Estrogen receptor positive tumors must demonstrate progression on at least 1
                       hormonal manipulation

        PATIENT CHARACTERISTICS:

        Age

          -  18 to 60

        Sex

          -  Female

        Menopausal status

          -  Not specified

        Performance status

          -  Karnofsky 70-100% OR

          -  ECOG 0-1

        Life expectancy

          -  Not specified

        Hematopoietic

          -  WBC at least 1,500/mm^3

          -  Platelet count at least 30,000/mm^3

        Hepatic

          -  Bilirubin less than 3 times normal*

          -  AST and ALT less than 3 times normal* NOTE: *Unless abnormality due to malignancy

        Renal

          -  Creatinine no greater than 1.6 mg/dL

        Cardiovascular

          -  LVEF greater than 40% by echocardiography or MUGA

          -  No myocardial infarction within the past 6 months

        Pulmonary

          -  DLCO greater than 40% of predicted

        Other

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  HIV negative

          -  No serious localized or systemic infection

          -  No hypersensitivity to E. coli-derived products

          -  No history of non-breast malignant disease within the past 5 years except completely
             excised nonmelanoma skin cancer or carcinoma in situ of the cervix

          -  No chronic inflammatory disorder requiring concurrent glucocorticosteroids or other
             immunosuppressive medication

          -  No psychological condition or social situation that would preclude study participation

        PRIOR CONCURRENT THERAPY:

        Biologic therapy

          -  Not specified

        Chemotherapy

          -  See Disease Characteristics

        Endocrine therapy

          -  No concurrent glucocorticoids

        Radiotherapy

          -  No prior radiotherapy to an indicator lesion unless the lesion shows evidence of
             progression after discontinuation of the therapy

        Surgery

          -  Not specified

        Other

          -  No concurrent immunosuppressive medication
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Edward D. Ball, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Diego</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Rebecca and John Moores UCSD Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093-0658</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2014</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 10, 2003</study_first_submitted>
  <study_first_submitted_qc>December 10, 2003</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 11, 2003</study_first_posted>
  <results_first_submitted>May 29, 2014</results_first_submitted>
  <results_first_submitted_qc>November 20, 2014</results_first_submitted_qc>
  <results_first_posted type="Estimate">November 24, 2014</results_first_posted>
  <last_update_submitted>December 2, 2014</last_update_submitted>
  <last_update_submitted_qc>December 2, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, San Diego</investigator_affiliation>
    <investigator_full_name>Edward Ball</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>recurrent breast cancer</keyword>
  <keyword>stage IV breast cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Melphalan</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The protocol recruited patients with Metastatic breast cancer for transplant after ATG, high-dose Melphalan and Fludarabine.This was a non-randomized, single arm pilot study. Patients received fludarabine IV days -8 to -4, ATG IV on days -7 to -4 and High dose Melphalan days -3 to -2. This protocol is closed to accrual as of March 2008</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Treatment</title>
          <description>anti-thymocyte globulin
filgrastim
graft-versus-tumor induction therapy
therapeutic allogeneic lymphocytes
cyclosporine
fludarabine phosphate
melphalan
methotrexate
peripheral blood stem cell transplantation</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>This is a pilot study. The original planned target accrual was 15 male or female patients age 18-60 but due to poor enrollment the study was closed to accrual early after 5 patients had been enrolled.</population>
      <group_list>
        <group group_id="B1">
          <title>Pilot Study of Allogeneic Transplant for Metastatic Breast Can</title>
          <description>anti-thymocyte globulin
filgrastim
graft-versus-tumor induction therapy
therapeutic allogeneic lymphocytes
cyclosporine
fludarabine phosphate
melphalan
methotrexate
peripheral blood stem cell transplantation</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Median</param>
          <dispersion>Full Range</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45" lower_limit="40" upper_limit="57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Adverse Events Rate</title>
        <time_frame>5 years post transplant</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Treatment</title>
            <description>Toxicity
anti-thymocyte globulin
filgrastim
graft-versus-tumor induction therapy
therapeutic allogeneic lymphocytes
cyclosporine
fludarabine phosphate
melphalan
methotrexate
peripheral blood stem cell transplantation</description>
          </group>
        </group_list>
        <measure>
          <title>Adverse Events Rate</title>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Facilitation of Long-term Engraftment</title>
        <time_frame>post treatment</time_frame>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Incidence and Severity of Acute and Chronic Graft-versus-host Disease (GVHD)</title>
        <time_frame>post treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Progression-free Survival</title>
        <time_frame>post treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival</title>
        <time_frame>post treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Response (Partial and Complete) as Measured at 1, 3, 6, and 12 Months Post Allografting and Within 1 Week After the Onset of Documented GVHD if &gt; 1 Month Separates Any of the Response Evaluation Timepoints</title>
        <time_frame>post treatment</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Frequency and Durability of the Induction of Full Donor Chimerism of Lymphocytes as Measured at 1, 3, 6, and 12 Months Post Allografting</title>
        <time_frame>post treatment</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <desc>AEs and SAEs collected on all Patients</desc>
      <group_list>
        <group group_id="E1">
          <title>Treatment</title>
          <description>incidence of Toxicity
administration of filgrastim
Grade of GVHD
Initiation of graft-versus-tumor induction therapy
Disease Status</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Terminated early due to small numbers of subjects enrolled on study</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Edward Ball, Director BMT Program</name_or_title>
      <organization>UCSD</organization>
      <phone>858-822-6600</phone>
      <email>tball@ucsd.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

